Biocon Biologics gets eight observations from USFDA for Malaysia insulin facility

The US drug regulator issued 6 observations for drug substance, drug product units and quality Control laboratories and 2 observations for the delivery devices unit of Biocon Sdn Bhd, Malaysia, a subsidiary of Biocon Biologics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jrB5781
via IFTTT